Dupuis Jehan, Gaulard Philippe, Hemery Francois, Itti Emmanuel, Gisselbrecht Christian, Rahmouni Alain, Copie-Bergman Christiane, Brière Josette, El Gnaoui Taoufik, Gaillard Isabelle, Meignan Michel, Haioun Corinne
Departments of Clinical Hematology, Hôpital H. Mondor, Paris XII University, Créteil, France.
Haematologica. 2007 Jun;92(6):778-83. doi: 10.3324/haematol.10895.
Diffuse large B-cell lymphomas (DLBCL) have a variable outcome, and powerful methods of prognostication are needed in order to choose the best treatment for each patient. Immunophenotypic classification of the tumor as germinal center (GC) or non-germinal center-like (nGC) and early response evaluation with 18fluorodeoxyglucose positron emission tomography (18FDG-PET) scanning have been correlated with survival in DLBCL but the two methods have never been evaluated simultaneously in the same patient population. Our aim was to investigate their respective prognostic values in the same series of patients.
We investigated the expression of CD10, Bcl-6, and MUM1 in 81 patients with DLBCL evaluated early with 18FDG-PET. The tumors were classified as GC or nGC using the algorithm of Hans et al. The results of both methods were correlated with the patients' characteristics and survival.
CD10 was positive in 27/76 (36%), Bcl-6 in 43/74 (58%), and MUM1 in 33/73 (45%) interpretable cases. Thirty-eight (51%) were in the GC group, and 36 (49%) in the nGC group. With a median follow-up of 33 months, estimated 3-year event-free survival (EFS) of the whole population was 67%. There was no influence of GC/nGC phenotype on survival. Three-year EFS was 46% in the early PET-positive group versus 80% in the PET-negative group (p=0.0003).
The prognostic value of GC/nGC phenotype is not confirmed in this heterogeneous series, whereas early PET findings are confirmed to be a powerful predictor of outcome. The impact of treatment decisions based on early PET results should be evaluated.
弥漫性大B细胞淋巴瘤(DLBCL)的预后各不相同,因此需要强有力的预后评估方法,以便为每位患者选择最佳治疗方案。肿瘤的免疫表型分类为生发中心(GC)型或非生发中心样(nGC)型,以及采用18氟脱氧葡萄糖正电子发射断层扫描(18FDG-PET)进行早期反应评估,均已被证明与DLBCL患者的生存率相关,但这两种方法从未在同一患者群体中同时进行评估。我们的目的是在同一组患者中研究它们各自的预后价值。
我们对81例早期接受18FDG-PET评估的DLBCL患者的CD10、Bcl-6和MUM1表达情况进行了研究。采用Hans等人的算法将肿瘤分为GC型或nGC型。将两种方法的结果与患者的特征和生存率进行关联分析。
在76例可评估病例中,CD10阳性的有27例(36%),Bcl-6阳性的有43例(58%),MUM1阳性的有33例(45%)。38例(51%)属于GC组,36例(49%)属于nGC组。中位随访时间为33个月,整个人群的估计3年无事件生存率(EFS)为67%。GC/nGC表型对生存率没有影响。早期PET阳性组的3年EFS为46%,而PET阴性组为80%(p=0.0003)。
在这个异质性队列中,未证实GC/nGC表型的预后价值,而早期PET结果被证实是一个强有力的预后预测指标。应评估基于早期PET结果做出治疗决策的影响。